Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414919 · ClinicalTrials.gov registry record
Duration of Use of Highly Effective Reversible Contraception
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 13,880
- Enrollment target
NCT02414919: Completed study, sponsored by Bayer.
NCT02414919 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 13,880 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02414919 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 13,880 participants
- Enrollment target
Study Summary
To assess the proportion of women who use HERC for ≥2 years of duration
Interventions
- DRUG ParaGard
- DRUG Mirena (Levonorgestrel IUS, BAY86-5028)
- DRUG Implanon/Nexplanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,880 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2016-03-28 |
What the finished NCT02414919 record still lists
NCT02414919 is an observational study that tracks outcomes without assigning an intervention. Its 13,880 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which ParaGard is the first listed.
NCT02414919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02414919 about?
NCT02414919 is a clinical study titled "Duration of Use of Highly Effective Reversible Contraception". To assess the proportion of women who use HERC for ≥2 years of duration
What is the current status of trial NCT02414919?
This trial is currently completed. The enrollment target is 13,880 participants. The study started on 2015-04-01. Estimated completion is 2016-03-28.
What interventions are being tested in trial NCT02414919?
The interventions under investigation include: ParaGard (DRUG), Mirena (Levonorgestrel IUS, BAY86-5028) (DRUG), Implanon/Nexplanon (DRUG).
Who is sponsoring clinical trial NCT02414919?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI